Abstract
New resistance problems have emerged recently among hospital and community-acquired pathogens such as in Staphylococcus aureus, Enterococcus faecium and Pseudomonas aeruginosa. Hospital-acquired and now community-acquired methicillin-resistant S. aureus are emerging worldwide whereas vancomycin-resistant S. aureus remain extremely rare. Hospital-acquired outbreaks of vancomycin-resistant enterococci and multidrug resistant Pseudomonas aeruginosa infections are increasingly reported worldwide. Whereas novel molecules are being developed for treating Gram-positive infections, difficult to non possible-to-treat pandrug-resistant P. aeruginosa infections may become a therapeutic challenge soon.
MeSH terms
-
Community-Acquired Infections / drug therapy
-
Community-Acquired Infections / epidemiology
-
Community-Acquired Infections / microbiology
-
Cross Infection / drug therapy
-
Cross Infection / epidemiology
-
Cross Infection / microbiology*
-
Drug Resistance, Multiple, Bacterial*
-
Enterococcus / classification
-
Enterococcus / drug effects*
-
Enterococcus / isolation & purification
-
Gram-Positive Bacterial Infections / drug therapy
-
Gram-Positive Bacterial Infections / epidemiology
-
Gram-Positive Bacterial Infections / microbiology
-
Methicillin Resistance
-
Pseudomonas Infections / drug therapy
-
Pseudomonas Infections / epidemiology
-
Pseudomonas Infections / microbiology
-
Pseudomonas aeruginosa / classification
-
Pseudomonas aeruginosa / drug effects*
-
Pseudomonas aeruginosa / isolation & purification
-
Staphylococcal Infections / drug therapy
-
Staphylococcal Infections / epidemiology
-
Staphylococcal Infections / microbiology
-
Staphylococcus aureus / classification
-
Staphylococcus aureus / drug effects*
-
Staphylococcus aureus / isolation & purification
-
Vancomycin Resistance